Jupe - I think the limited sample sizes on which some of the BoM results are based is a concern which is why I downgraded my goofy buyout valuation by a couple of billion.  I suppose you could downgrade it by another billion to account for what may be an overinflated valuation opinion by DM of the $4B number.  However, there does seem to be enough evidence over that attests to the significant overall 'potential' of apabetalone across a number of high value indications.  The big question is, what is it worth at this stage.....$2B or $20B?